This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
New Strong Buy Stocks For August 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 PEG-Driven Value Stocks to Invest in Coronavirus-Hit Market
by Urmimala Biswas
PEG ratio is complicated, considering the limitations in calculating the future earnings growth potential of a stock.
The Zacks Analyst Blog Highlights: Best Buy, Activision Blizzard, DaVita, Micron and PulteGroup
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Best Buy, Activision Blizzard, DaVita, Micron and PulteGroup
5 Top Stocks to Buy as S&P 500 Nears an All-Time High
by Tirthankar Chakraborty
Given that the S&P 500 is close to its first record close in six months as hopes rise for economic stimulus and a COVID-19 vaccine, investing in some of the top stocks listed in the index seems wise.
6 Stocks Trading Near 52-Week Highs That Can Rally Further
by Anirudha Bhagat
Investors target stocks that have been on a bullish run lately. Stocks seeing price strength have higher chances of carrying the momentum forward.
The Zacks Analyst Blog Highlights: DaVita, PayPal, Century Communities, Berry Global and Turning Point Brands
by Tirthankar Chakraborty
The Zacks Analyst Blog Highlights: DaVita, PayPal, Century Communities, Berry Global and Turning Point Brands
Buy These 5 Stocks Before It's Too Late
by Sejuti Banerjea
With solid earnings beats and upward revisions in estimates, these stocks are worth adding to your portfolio.
New Strong Buy Stocks For August 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is DaVita HealthCare (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
DaVita HealthCare (DVA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States were solid in Q2.
DaVita HealthCare (DVA) Beats Q2 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 51.16% and -1.13%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance within net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in Q2.
DaVita HealthCare (DVA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis
by Sriparna Ghosal
Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.
Top Ranked Growth Stocks to Buy for July 9th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, July 9th.
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
3 Affordable MedTech Growth Stocks to Buy Amid Market Unrest
by Debanjana Dey
Here are some MedTech stocks which might be a solid investment option amid the coronavirus-battered market conditions.
New Strong Buy Stocks For July 8th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Is DaVita (DVA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (DVA) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain DaVita in Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA), thanks to solid prospects.
Here's Why You Should Retain VEEVA Systems (VEEV) Stock Now
by Zacks Equity Research
Investor confidence is high in VEEVA Systems (VEEV), thanks to solid prospects.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?